Abstract
Gains in overall and progression-free survival (OS, PFS) and a higher objective response rate were observed in the CASPIAN trial of patients with extensive-stage small-cell lung cancer who received durvalumab in combination with etoposide and platinum-based chemotherapy (D+EP) compared with EP alone. However, the extent to which response predicts long-term survival is unknown. We defined response/non-response at different landmark times and derived OS and PFS during follow-up after each landmark among D+EP and EP patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
